A comparison of acrivastine versus chlorpheniramine in the treatment of chronic idiopathic urticaria.
A total of 20 patients with a diagnosis of chronic idiopathic urticaria were entered into a fully randomized, double-blind, crossover study to investigate the efficacy of 8 mg acrivastine versus 4 mg chlorpheniramine three times daily. Data from 16 patients were available for analysis. Both acrivastine and chlorpheniramine were found to be effective in relieving the signs and symptoms of urticaria. There were no significant differences between the two treatments, although efficacy trends were generally in favour of acrivastine over chlorpheniramine throughout the study.
Gale
A E
AE
Adelaide Aerobiology Laboratory, Hindmarsh, South Australia.
Harvey
S G
SG
Calthrop
J G
JG
Gibson
J R
JR
D000328:Adult; D002744:Chlorpheniramine / Q000627:therapeutic use*; D002908:Chronic Disease; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D005260:Female; D006634:Histamine H1 Antagonists / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D011725:Pyridines / Q000627:therapeutic use*; D011897:Random Allocation; D014311:Triprolidine / Q000031:analogs & derivatives / Q000627:therapeutic use*; D014581:Urticaria / Q000188:drug therapy*
D006634:Histamine H1 Antagonists; D011725:Pyridines; D014311:Triprolidine; D002744:Chlorpheniramine; C043648:acrivastine